Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Kim, Bong-Seog | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Kim, Hee-Jun | - |
dc.contributor.author | Lee, Hyo Jin | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Yoon, Shinkyo | - |
dc.contributor.author | Hong, Bumsik | - |
dc.contributor.author | Hong, Jun Hyuk | - |
dc.contributor.author | Ahn, Hanjong | - |
dc.contributor.author | Lee, Jae Lyun | - |
dc.date.accessioned | 2021-08-31T08:53:00Z | - |
dc.date.available | 2021-08-31T08:53:00Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57514 | - |
dc.description.abstract | Purpose: Gemcitabineeoxaliplatin (GEMOX) demonstrated mild toxicity and promising effectiveness in patients with advanced urothelial cell cancer (UCC). We investigated the activity and safety of first-line GEMOX compared with gemcitabine-carboplatin (GCb) in cisplatin-ineligible patients with advanced UCC. Methods: Treatment-naive, cisplatin-ineligible patients with advanced UCC were randomly assigned to GEMOX (gemcitabine 1000 mg/m(2), oxaliplatin 100 mg/m(2) on day 1 [D1] every 2 weeks) or GCb (1000 mg/m(2) of gemcitabine on D1 and D8 and carboplatin area under the curve of 4.5 mg/mL/min on D1 every 3 weeks). We evaluated the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: Between January 2011 and March 2017, 80 patients were enrolled; 39 and 40 patients were allocated to GCb and GEMOX arms, respectively. The ORR was 48.7% in the GCb arm and 55.0% in the GEMOX arm. The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months (95% confidence interval [CI], 4.8 -6.2) vs. 4.4 months (95% CI, 2.7-6.1) and 9.1 months (95% CI, 5.2-13.0) vs. 11.0 months (95% CI, 6.9-15.0), respectively. >= Leucopenia, neutropenia and fatigue of >= grade III were significantly more common in the GCb arm (26% vs. 3%, P = 0.003; 33% vs. 10%, P = 0.014; 15% vs. 3%, P = 0.012), whereas any-grade neuropathy was more common in the GEMOX arm (8% vs. 60%). Conclusions: GEMOX showed similar efficacy with GCb and a favourable haematologic toxicity profile. GEMOX may be an additional chemotherapy option for patients with UCC ineligible for cisplatin-containing chemotherapy (C) 2019 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | TRANSITIONAL-CELL CARCINOMA | - |
dc.subject | 1ST-LINE TREATMENT | - |
dc.subject | CANCER | - |
dc.subject | COMBINATION | - |
dc.subject | MULTICENTER | - |
dc.subject | TRIAL | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | METHOTREXATE | - |
dc.subject | VINBLASTINE | - |
dc.subject | DOXORUBICIN | - |
dc.title | Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.identifier.doi | 10.1016/j.ejca.2019.08.034 | - |
dc.identifier.scopusid | 2-s2.0-85074427378 | - |
dc.identifier.wosid | 000514572100019 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, v.127, pp.183 - 190 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.title | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.volume | 127 | - |
dc.citation.startPage | 183 | - |
dc.citation.endPage | 190 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TRANSITIONAL-CELL CARCINOMA | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | VINBLASTINE | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordAuthor | Urothelial cancer | - |
dc.subject.keywordAuthor | Cisplatin-unfit | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | Carboplatin | - |
dc.subject.keywordAuthor | Gemcitabine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.